Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurix Therapeutics Inc (NRIX)

Nurix Therapeutics Inc (NRIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Nurix Therapeutics Inc 1600 SIERRA POINT PKWY BRISBANE CA 94005 USA

www.nurixtx.com Employees: 317 P: 415-660-5320 F: 415-525-4200

Sector:

Medical

Description:

Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California.

Key Statistics

Overview:

Market Capitalization, $K 1,635,204
Enterprise Value, $K 1,388,244
Shares Outstanding, K 102,843
Float, K 95,233
% Float 92.60%
Short Interest, K 15,248
Short Float 14.83%
Days to Cover 17.99
Short Volume Ratio 0.64
% of Insider Shareholders 7.40%
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 83,980 K
Annual Net Income, $ -264,460 K
Last Quarter Sales, $ 13,580 K
Last Quarter Net Income, $ -78,220 K
EBIT, $ -285,670 K
EBITDA, $ -277,140 K

Growth:

1-Year Return 14.75%
3-Year Return 77.03%
5-Year Return -51.75%
5-Year Revenue Growth 371.27%
5-Year Earnings Growth -10.51%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.03 on 10/09/25
Next Earnings Date 04/14/26
Earnings Per Share ttm -3.04
EPS Growth vs. Prev Qtr 20.39%
EPS Growth vs. Prev Year -9.33%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

NRIX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -57.51%
Return-on-Assets % -43.76%
Profit Margin % -314.91%
Debt/Equity 0.00
Price/Sales 18.98
Price/Cash Flow N/A
Price/Book 2.93
Book Value/Share 5.29
Interest Coverage -4.00
60-Month Beta 1.96
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar